CC-99282: A phase 1 trial of CC-99282 alone and in combination with anti-lymphoma agents in people with relapsed or refractory non-Hodgkin lymphoma
A phase 1/2 trial evaluating CC-99282 in people with relapsed or refractory non-Hodgkin lymphoma.
You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT03930953
Trial aim and background
The aim of this trial is to find out the safety and efficacy of CC-99282 alone and in combination with anti-lymphoma agents in adults with non-Hodgkin lymphoma that has either come back (relapsed) or not responded to previous treatment (refractory).
This is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.
Who can enter
Adults with non-Hodgkin Lymphoma (NHL) which has relapsed or become refractory to treatment may be eligible for this trial.
Locations
Recruitment is taking place in the following UK locations:
- Edinburgh
- Southampton
Further information
More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/ct2/show/NCT03930953
Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.